Safety of insulin analogues as compared with human insulin in pregnancy

References

• American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Supplement_1):S8–S16.
   Web of Science ®Google Scholar
• Lawrence JM, Contreras R, Chen W, et al. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005. Diabetes Care. 2008;31(5):899–904.
   PubMed Web of Science ®Google Scholar
• Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915.
   PubMed Web of Science ®Google Scholar
• Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27:2819–2823.
   PubMed Web of Science ®Google Scholar
• Farrell T, Neale L, Cundy T. Congenital anomalies in the offspring of women with type 1, type 2 and gestational diabetes. Diabet Med. 2002;19(4):322–326.
   PubMed Web of Science ®Google Scholar
• Tennant PW, Glinianaia SV, Bilous RW, et al. Pre-existing diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: a population-based study. Diabetologia. 2014;57(2):285–294.
   PubMed Web of Science ®Google Scholar
• Dudley DJ. Diabetic-associated stillbirth: incidence, pathophysiology, and prevention. Obstet Gynecol Clin North Am. 2007;34(2):293–307.
   PubMed Web of Science ®Google Scholar
• Kitzmiller JL, Buchanan TA, Kjos S, et al. Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996;19(5):514–541.
   PubMed Web of Science ®Google Scholar
• Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care. 2006;29(8):1744–1749.
   PubMed Web of Science ®Google Scholar
• Page RC, Kirk BA, Fay T, et al. Is macrosomia associated with poor glycaemic control in diabetic pregnancy? Diabet Med. 1996;13(2):170–174.
   PubMed Web of Science ®Google Scholar
• Greene MF. Spontaneous abortions and major malformations in women with diabetes mellitus. Semin Reprod Endocrinol. 1999;17(2):127–136.
   PubMedGoogle Scholar
• Group HSCR, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Caritis SN, Hauth JC, et al. Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The national institute of child health and human development maternal- fetal medicine units network. Am J Obstet Gynecol. 2000;183(6):1520–1524.
   PubMed Web of Science ®Google Scholar
• de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–1241.
   PubMed Web of Science ®Google Scholar
• Combs CA, Gunderson E, Kitzmiller JL, et al. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–1257.
   PubMed Web of Science ®Google Scholar
• Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development– Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991;164(1 Pt 1):103–111.
   PubMed Web of Science ®Google Scholar
• Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003;189:507–512.
   PubMed Web of Science ®Google Scholar
• Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328(7445):915.
   PubMed Web of Science ®Google Scholar
• Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med. 2005;10(4):333–339.
   PubMed Web of Science ®Google Scholar
• McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med. 2000;9(1):14–20.
   PubMedGoogle Scholar
• Jensen DM, Damm P, Sorensen B, et al. Clinical impact of mild carbohydrate intolerance in pregnancy: a study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus. Am J Obstet Gynecol. 2001;185(2):413–419.
   PubMed Web of Science ®Google Scholar
• Jensen DM, Korsholm L, Ovesen P, et al. Adverse pregnancy outcome in women with mild glucose intolerance: is there a clinically meaningful threshold value for glucose? Acta Obstet Gynecol Scand. 2008;87(1):59–62.
   PubMed Web of Science ®Google Scholar
• Ferrara A, Weiss NS, Hedderson MM, et al. Pregnancy plasma glucose levels exceeding the american diabetes association thresholds, but below the national diabetes data group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. Diabetologia. 2007;50(2):298–306.
   PubMed Web of Science ®Google Scholar
• Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The toronto tri-hospital gestational diabetes project. Am J Obstet Gynecol. 1995;173(1):146–156.
   PubMed Web of Science ®Google Scholar
• Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabet Care. 2004;27(12):2819–2823.
   PubMed Web of Science ®Google Scholar
• Hartling L, Dryden DM, Guthrie A, et al. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. preventive services task force and the national institutes of health office of medical applications of research. Ann Intern Med. 2013;159(2):123–129.
   PubMed Web of Science ®Google Scholar
• Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31:1060–1079.
   PubMed Web of Science ®Google Scholar
• Klemetti MM, Laivuori H, Tikkanen M, et al. White’s classification and pregnancy outcome in women with type 1 diabetes: a population-based cohort study. Diabetologia. 2016;59(1):92–100.
   PubMed Web of Science ®Google Scholar
• Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–1138.
   PubMed Web of Science ®Google Scholar
• Langer O, Yogev Y, Xenakis EM, et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol. 2005;192(1):134–139.
   PubMed Web of Science ®Google Scholar
• Knox CA, Delaney JA, Winterstein AG. Anti-diabetic drug utilization of pregnant diabetic women in us managed care. BMC Pregnancy Childbirth. 2014;14:28.
   PubMed Web of Science ®Google Scholar
• Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31(5):1060–1079.
   PubMed Web of Science ®Google Scholar
• Lambert K, Holt RI. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013;15(10):888–900.
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183.
   PubMed Web of Science ®Google Scholar
• Evers IM, ter Braak EW, de Valk HW, et al. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care. 2002;25(3):554–559.
   PubMed Web of Science ®Google Scholar
• Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycaemia during pregnancy in women with Type 1 diabetes. Diabet Med. 2012;29(5):558–566.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47(4):622–629.
   PubMed Web of Science ®Google Scholar
• Home PD, Lindholm A, Riis A, European Insulin Aspart Study G. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Med. 2000;17(11):762–770.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24(4):631–636.
   PubMed Web of Science ®Google Scholar
• Torlone E, Di Cianni G, Mannino D, et al. Insulin analogs and pregnancy: an update. Acta Diabetol. 2009;46(3):163–172.
   PubMed Web of Science ®Google Scholar
• Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;198(2):186e1–7.
   Web of Science ®Google Scholar
• Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30(4):771–776.
   PubMed Web of Science ®Google Scholar
• Di Cianni G, Volpe L, Ghio A, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care. 2007;30(4):e11.
   PubMed Web of Science ®Google Scholar
• Mecacci F, Carignani L, Cioni R, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol. 2003;111(1):19–24.
   PubMed Web of Science ®Google Scholar
• Murphy HR, Elleri D, Allen JM, et al. Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia. 2012;55:282–293.
   PubMed Web of Science ®Google Scholar
• Lapolla A, Dalfra MG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008;45:61–66.
   PubMed Web of Science ®Google Scholar
• Durnwald CP, Landon MB. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med. 2008;21:309–313.
   PubMed Web of Science ®Google Scholar
• Cypryk K, Sobczak M, Pertynska-Marczewska M, et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit. 2004;10:I29–I32.
   Web of Science ®Google Scholar
• Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2002;58:115–121.
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Immonen I, Teramo KA, et al. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care. 2003;26:1193–1198.
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care. 1999;22:1422–1427.
   PubMed Web of Science ®Google Scholar
• Aydin Y, Berker D, Direktor N, et al. Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract. 2008;80:444–448.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Brown S, Hughes S, et al. Insulin lispro and regular insulin in pregnancy. QJM. 2001;94:255–260.
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Lankisch MR, Pawlowski B, et al. Insulin Lispro in pregnancy – retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes. 2002;110:6–9.
   PubMed Web of Science ®Google Scholar
• Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care. 2010;33:473–477.
   PubMed Web of Science ®Google Scholar
• Pettitt DJ, Ospina P, Howard C, et al. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24:1129–1135.
   PubMed Web of Science ®Google Scholar
• Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26:183–186.
   PubMed Web of Science ®Google Scholar
• Balaji V, Balaji MS, Alexander C, et al. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol. 2012;28:529–532.
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Hadden DR. Diabetes in pregnancy 1985. Diabetologia. 1986;29:1–9.
   PubMed Web of Science ®Google Scholar
• Poyhonen-Alho M, Ronnemaa T, Saltevo J, et al. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand. 2007;86:1171–1174.
   PubMed Web of Science ®Google Scholar
• Imbergamo MP, Amato MC, Sciortino G, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 2008;30:1476–1484.
   PubMed Web of Science ®Google Scholar
• Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 2007;114:453–457.
   PubMed Web of Science ®Google Scholar
• Fang YM, MacKeen D, Egan JF, et al. Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med. 2009;22:249–253.
   PubMed Web of Science ®Google Scholar
• Negrato CA, Rafacho A, Negrato G, et al. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89:46–51.
   PubMed Web of Science ®Google Scholar
• Smith JG, Manuck TA, White J, et al. Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol. 2009;26:57–62.
   PubMed Web of Science ®Google Scholar
• Egerman RS, Ramsey RD, Kao LW, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol. 2009;26:591–595.
   PubMed Web of Science ®Google Scholar
• Lepercq J, Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012;2012:649070.
   PubMedGoogle Scholar
• Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol. 2002;21:181–189.
   PubMed Web of Science ®Google Scholar
• Koren R, Toledano Y, Hod M. The use of insulin detemir during pregnancy: a safety evaluation. Expert Opin Drug Saf. 2015;14(4):593–599.
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012–2017.
   PubMed Web of Science ®Google Scholar
• Mathiesen ER, Damm P, Jovanovic L, et al. Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes. Diabetes Metab Res Rev. 2011;27:543–551.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622–629.
   PubMed Web of Science ®Google Scholar
• Bartley PC, Bogoev M, Larsen J, et al. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25:442–449.
   PubMed Web of Science ®Google Scholar
• Callesen NF, Damm J, Mathiesen JM, et al. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med. 2013;26(6):588–592.
   PubMed Web of Science ®Google Scholar
• Herrera KM, Rosenn BM, Foroutan J, et al. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol. 2015. doi:10.1016/j.ajog.2015.06.010.
   PubMed Web of Science ®Google Scholar
• Hod M, Mathiesen ER, Jovanovič L, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med. 2014;27(1):7–13.
   PubMed Web of Science ®Google Scholar
• Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas. 2002;41(Suppl 1):S65–S83.
   PubMed Web of Science ®Google Scholar
• Colatrella A, Visalli N, Abbruzzese S, et al. Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol. 2013;2013:151975.
   PubMed Web of Science ®Google Scholar
• Dalfrà MG, Soldato A, Moghetti P, et al. Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. J Matern Fetal Neonatal Med. 2015;21:1–5.
   Google Scholar
• Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227–4249.
   PubMed Web of Science ®Google Scholar
• Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. 2010;33:29–33.
   PubMed Web of Science ®Google Scholar
• NICE guideline. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. National Institute for Health and Care Excellence, 2015. Available from: nice.org.uk/guidance/ng3
   Google Scholar
• Suffecool K, Rosenn B, Niederkofler EE, et al. Insulin detemir does not cross the human placenta. Diabetes Care. 2015;38(2):e20–e21. doi:10.2337/dc14-2090.
   Google Scholar
• Lawrence JM, Contreras R, Chen W, et al. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care. 2008;31(5):899–904.
   PubMed Web of Science ®Google Scholar
• Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30(Suppl 2):S141–S146.
   PubMed Web of Science ®Google Scholar
• Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191–204.
   PubMedGoogle Scholar
• Thalange N, Deeb L, Iotova V, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16(3):164–176.
   PubMed Web of Science ®Google Scholar
• Concentrated insulin glargine (Toujeo) for diabetes. Med Lett Drugs Ther. 2015;57(1468):69–70.
   PubMedGoogle Scholar
• Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244–2253.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Humalog® 200 U/ml KwikPen™. Rev Med Liege. 2015;70(10):527–531.
   PubMedGoogle Scholar
• Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: A randomized, titration-to-target clinical trial. Endocr Pract. 2015;21(7):782–793.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Battelino T, Danne T, et al. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2015. doi:10.1002/dmrr.2653.
   Web of Science ®Google Scholar